CollPlant Biotechnologies has announced encouraging non-clinical results for its photocurable regenerative dermal and soft tissue filler. The company is preparing for clinical trials, a key step toward transforming the future of aesthetic and regenerative treatments. A new era in filler technology CollPlant Biotechnologies’ innovation stands out for combining precision contouring, strong structural support, and natural tissue regeneration in a single ...
“Guidance Regarding SARS-CoV-2 mRNA Vaccine Side Effects in Dermal Filler Patients”, provides data from the US Food and Drug Administration (FDA) on reactions from the mRNA vaccine. It also shares information for both dermal practitioners and patients about the occurrence of reactions based on the latest data available. The FDA data reports show that three participants out of 15,184 who ...